Heart attacks (myocardial infarctions) are acute events caused by reduced or blocked coronary blood flow leading to ischemic injury of heart muscle. They are a major cause of morbidity and mortality and require urgent diagnosis and reperfusion-oriented treatment. Risk factors overlap with broader cardiovascular disease risk.
A phase 3 trial shows that the oral drug enlicitide reduces LDL cholesterol by 60% compared to placebo, according to results published in the New England Journal of Medicine. Sponsored by Merck & Co., the trial involved 2,909 participants with atherosclerosis or at risk. If approved, enlicitide could help lower heart attack and stroke risk.
20/20 BioLabs began trading on Nasdaq under ticker AIDX and disclosed a contingent financing agreement of up to $40 million. It later signed an exclusive U.S. license deal with ROKIT to add CKD prediction to OneTest for Longevity.
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
New NICE guidance recommends offering SGLT-2 inhibitors earlier in type 2 diabetes treatment, potentially preventing 17,000 deaths over three years while saving the NHS £560 million through generic medicines.
The Mississippi Department of Environmental Quality issued an air permit to xAI for 41 gas turbines to power its Colossus II data center, despite a lawsuit threat from the NAACP alleging Clean Air Act violations and community concerns about air quality impacts.
Oral semaglutide reduced heart failure events by 22% in Type 2 diabetes patients with existing heart failure in a trial of nearly 9,650 adults, with particular benefit in HFpEF cases.
Health and Human Services Secretary Robert F. Kennedy Jr. announced plans to review the safety of ultra-processed foods, criticizing the GRAS exemption that allows companies to verify ingredient safety without FDA oversight since 1997.
A phase three clinical trial shows enlicitide, an oral monoclonal antibody, reduced LDL cholesterol by 60% compared to placebo in 2,909 patients with or at risk of atherosclerosis over 24 weeks.
A review in The Lancet highlights emerging long-acting injectable therapies for hypertension that could reduce treatment to two doses annually instead of daily pills, with several candidates now in late-stage clinical trials.
New research shows semaglutide cuts cardiovascular event risk by 4% per 5kg weight loss, with two-thirds of heart benefits unexplained by weight reduction alone. Study of 17,604 participants suggests multiple protective mechanisms beyond weight loss.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02376244 |
The Health Impact of High Intensity Exercise Training With Intervals During Cardiac Rehabilitation |
COMPLETED | NA |
